NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis

Company Overview

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Key Stats

• Today's Range: $1.21 to $1.25
• 50-Day Range: $0.71 to $1.35
• 52-Week Range: $0.43 to $2.33
• Volume: 65,885 shs
• Average Volume: 266,229 shs
• Market Capitalization: $17.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NeuroSense Therapeutics Stock Analysis - MarketRank™

NeuroSense Therapeutics scored higher than 23% of companies evaluated by MarketBeat, and ranked 876th out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NeuroSense Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroSense Therapeutics is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroSense Therapeutics is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.62% of the float of NeuroSense Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

NeuroSense Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroSense Therapeutics has recently decreased by 23.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroSense Therapeutics does not currently pay a dividend.

Dividend Growth

NeuroSense Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.62% of the float of NeuroSense Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

NeuroSense Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroSense Therapeutics has recently decreased by 23.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.16

News Sentiment

NeuroSense Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for NeuroSense Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

4 people have added NeuroSense Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeuroSense Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.40% of the stock of NeuroSense Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 1.04% of the stock of NeuroSense Therapeutics is held by institutions.

NRSN Stock Analysis - Frequently Asked Questions

How have NRSN shares performed this year?

NeuroSense Therapeutics' stock was trading at $0.7850 at the beginning of 2024. Since then, NRSN stock has increased by 59.2% and is now trading at $1.25.
View the best growth stocks for 2024 here.

When did NeuroSense Therapeutics IPO?

NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering on Thursday, December 9th 2021. The company issued 2,000,000 shares at a price of $6.00-$7.00 per share.

How do I buy shares of NeuroSense Therapeutics?

Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NeuroSense Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroSense Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Energy Select Sector SPDR Fund (XLE).

Company Calendar

• Today: 11/05/2024
• Next Earnings (Estimated): 11/26/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NRSN
• CUSIP: N/A
• CIK: 1875091
• Web: www.neurosense-tx.com
• Phone: 972-9799-6183
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,280,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -286.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.46
• Quick Ratio: 0.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.14) per share
• Price / Book: -8.93

Miscellaneous

• Outstanding Shares: 13,670,000
• Free Float: 9,922,000
• Market Cap: $17.09 million
• Optionable: Not Optionable
• Beta: 1.58